APRI (Aprinoia Therapeutics) Receivables Turnover: 0.49 (As of Dec. 2023)


What is Aprinoia Therapeutics Receivables Turnover?

Aprinoia Therapeutics APRI Receivables Turnover is 0.49 as of Dec. 2023.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Aprinoia Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.04 Mil. Aprinoia Therapeutics's average Accounts Receivable for the six months ended in Dec. 2023 was $0.07 Mil. Hence, Aprinoia Therapeutics's Receivables Turnover for the six months ended in Dec. 2023 was 0.49.

Aprinoia Therapeutics  (NAS:APRI) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Aprinoia Therapeutics Receivables Turnover Related Terms

Aprinoia Therapeutics Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Receivables Turnover Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Receivables Turnover
3.55 2.54 127.73

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Receivables Turnover 0.00 1.90 0.00 0.00 0.49

APRI vs : Receivables Turnover Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Receivables Turnover falls into.


Aprinoia Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Aprinoia Therapeutics's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Receivables Turnover (A: Dec. 2023 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2023 ) / ((Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count )
=9.069 / ((0 + 0.071) / 1 )
=9.069 / 0.071
=127.73

Aprinoia Therapeutics's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

Receivables Turnover (Q: Dec. 2023 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Dec. 2023 ) / ((Accounts Receivable (Q: Jun. 2023 ) + Accounts Receivable (Q: Dec. 2023 )) / count )
=0.035 / ((0 + 0.071) / 1 )
=0.035 / 0.071
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.49 mean?
Aprinoia Therapeutics (APRI) has a Receivables Turnover of 0.49 as of Dec. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Receivables Turnover too high?
Aprinoia Therapeutics' current Receivables Turnover is 0.49. The Biotechnology industry median Receivables Turnover is 5.28. Aprinoia Therapeutics' value of 0.49 is 90.7% below this industry median.
How does Aprinoia Therapeutics' Receivables Turnover compare to ?
Aprinoia Therapeutics' Receivables Turnover of 0.49 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. Aprinoia Therapeutics' value of 0.49 is 90.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprinoia Therapeutics's current Receivables Turnover of 0.49 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Aprinoia Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprinoia Therapeutics's current Receivables Turnover is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Receivables Turnover of 0.49. The current Receivables Turnover is 0.49 and 90.7% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Receivables Turnover is 0.49 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.